SEC Form 4 · accession 0001127602-19-001582
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve Aselage
Director
Period of report
Jan 4, 2019
Accepted (ET)
Jan 8, 2019 · 1:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock OptionF1 | $8.62 | Jan 4, 2019 | A | 25,000 | A | Jan 4, 2020 | Jan 4, 2029 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan.